Lazar Mandinov
Corporate Officer/Principal bei The European Society of Cardiology
Profil
Lazar Mandinov is a member of The European Society of Cardiology.
He previously worked as a Medical Director at Boston Scientific Corp., Chief Medical Officer at Mitralign, Inc., and Principal at Maine Medical Center Research.
Dr. Mandinov holds a doctorate degree from Medical University Sofia.
Aktive Positionen von Lazar Mandinov
| Unternehmen | Position | Beginn |
|---|---|---|
| The European Society of Cardiology | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Lazar Mandinov
| Unternehmen | Position | Ende |
|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
| Maine Medical Center Research | Corporate Officer/Principal | - |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Lazar Mandinov
| Medical University Sofia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BOSTON SCIENTIFIC CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
| The European Society of Cardiology | |
| Maine Medical Center Research |
